Physician profile
Tracy Williams
NPI 1962453431
$9,178.62
in general payments reported to CMS, 2019-2025
30 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,058 · 2022: $1,558 · 2023: $1,707 · 2024: $2,509 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,328 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,328.37 |
| Education | $233.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,173.34 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,198.00 | 2021-2025 | |
| Janssen Biotech, INC. | $982.51 | 2021-2025 | Tremfya |
| Ucb, INC. | $904.17 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $588.24 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $581.66 | 2021-2025 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $560.16 | 2023-2025 | |
| Pfizer INC. | $515.58 | 2021-2025 | |
| Organon LLC | $336.82 | 2021-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $299.14 | 2023-2025 | Benlysta, Nucala |
| Kiniksa Pharmaceuticals, LTD. | $182.77 | 2021-2023 | Arcalyst |
| Genentech USA, INC. | $120.11 | 2021-2025 | Actemra |
| Exeltis, USA INC. | $96.75 | 2024-2025 | Slynd, Twirla |
| Abbott Laboratories | $88.23 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $67.18 | 2022-2025 | Orencia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $65.70 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.68 | 2023-2025 | Cyltezo, Jascayd |
| Otsuka America Pharmaceutical, INC. | $56.01 | 2025 | Rexulti |
| Fresenius Kabi USA, LLC | $48.85 | 2023-2025 | Idacio, Tyenne |
| Kiniksa Pharmaceuticals International, Plc | $46.73 | 2024 | Arcalyst |
| Sandoz INC. | $28.58 | 2024-2025 | Hyrimoz, Jubbonti |
| Merck Sharp & Dohme LLC | $27.86 | 2021 | |
| Sobi, INC | $25.58 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.61 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.35 | 2023 | Inpefa |
| Gilead Sciences, INC. | $21.52 | 2021 | |
| Aurinia Pharma U.S., INC. | $17.92 | 2023 | Lupkynis |
| Collegium Pharmaceutical, INC. | $16.51 | 2024 | Belbuca |
| Radius Health, INC. | $13.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.89 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.